B cell immunopathology during HIV-1 infection: lessons to learn for HIV-1 vaccine design

Vaccine. 2008 Jun 6;26(24):3016-25. doi: 10.1016/j.vaccine.2007.11.063. Epub 2007 Dec 17.


Induction of broad HIV-1 neutralizing antibodies should be a major goal of an effective HIV-1 vaccine. However, B cells are severely damaged during HIV-1 infection with loss of memory B cells and decline of serological memory. The molecular events leading to B cell damage must be further characterized with the aim of selecting vaccine components allowing preservation of B cell functions. This review focuses on B cell damage and antibody responses in HIV-1-infected patients during vaccination studies with viral and bacterial antigens. In addition novel data indicate that B cell activation may be at the basis of impaired immune responses.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • AIDS Vaccines / immunology
  • B-Lymphocytes / immunology*
  • B-Lymphocytes / pathology
  • B-Lymphocytes / virology
  • CD4 Lymphocyte Count
  • CD4-Positive T-Lymphocytes / immunology
  • HIV Antibodies / biosynthesis
  • HIV Antibodies / immunology*
  • HIV Antigens / immunology
  • HIV Infections / immunology*
  • HIV Infections / pathology
  • HIV-1 / immunology*
  • Humans
  • Immunologic Memory
  • Lymphocyte Activation
  • Receptors, Chemokine / immunology


  • AIDS Vaccines
  • HIV Antibodies
  • HIV Antigens
  • Receptors, Chemokine